Technical collaborations
Welcome to the DCVMN Portal
Collaborations between members
This “Technical Collaborations space is an initiative aimed to share non-proprietary, non-confidential information that might be helpful in surge periods, such as outbreaks or seasonal peaks, or can facilitate accelerated access to vaccines in various presentations, through leveraging established capacities elsewhere.
This list only includes DCVMN member companies that voluntarily expressed their willingness to make available to other members their spare technical capabilities, such as filling of different containers types or packaging capabilities. All companies listed here have provided evidence of GMP compliance and valid GMP certification issued by their National Regulatory Agency.
Member companies not appearing in this portal may have their capacities fully committed or may have spare capacity for collaboration, but did not choose to appear in this space.
Please note the DCVMN disclaimer at the bottom of this page. Any communications from parties interested in collaboration should be addressed directly to the manufacturer, not to DCVMN. If you have suggestions for improvement of this Portal, or would like to be added to the database, please email: s.villasenor@dcvmn.net
| Company name | Technical capabilities |
|---|---|
 Beijing Minhai Biotechnology Co., Ltd. | CONTAINERS: Glass Syringe, Glass Vials, Ampoule FORMULATION: Adjuvants, Lyophilization, Conjugation CAPACITY: Analytical Testing, Drug Substance Production, Drug Product Production |
 China National Biotec Group Company Limited | CONTAINERS: Glass Syringe, Glass Vials, Ampoule, Plastic Dropper FORMULATION: Adjuvants, Preservatives, Lyophilization, Conjugation CAPACITY: Secondary packaging, Analytical Testing, Drug Substance Production, Drug Product Production |
 Company for Vaccine and Biological Production No1 (VABIOTECH) | CONTAINERS: Glass Vials FORMULATION: Adjuvants, Preservatives CAPACITY: Secondary packaging, Analytical Testing, Drug Substance Production, Drug Product Production |
 EuBiologics Co., Ltd | CONTAINERS: Plastic Vial FORMULATION: CAPACITY: Analytical Testing, Drug Substance Production |
 GC Pharma | CONTAINERS: Glass Syringe, Glass Vials FORMULATION: Adjuvants, Preservatives, Lyophilization CAPACITY: Secondary packaging, Analytical Testing, Drug Product Production |
 Incepta Vaccine Ltd | CONTAINERS: Glass Vials, Ampoule FORMULATION: Adjuvants, Preservatives, Lyophilization, Conjugation CAPACITY: Secondary packaging, Analytical Testing, Drug Substance Production, Drug Product Production |
 Institute of Medical Biology, Chinese Academy of Medical Sciences | CONTAINERS: Glass Syringe, Glass Vials, Plastic Dropper FORMULATION: Adjuvants, Preservatives, Lyophilization CAPACITY: Analytical Testing, Drug Substance Production, Drug Product Production |
 Korea Vaccine Co., Ltd. | CONTAINERS: Glass Syringe, Glass Vials FORMULATION: Lyophilization CAPACITY: Secondary packaging, Analytical Testing, Drug Product Production |
 Liaoning Cheng Da Biotechnology Co., Ltd | CONTAINERS: Glass Vials FORMULATION: Lyophilization CAPACITY: Analytical Testing, Drug Substance Production, Drug Product Production |
 Medigen Vaccine Biologics Corporation | CONTAINERS: Glass Syringe, Glass Vials FORMULATION: Adjuvants CAPACITY: Analytical Testing, Drug Substance Production, Drug Product Production |
 Panacea Biotec Limited | CONTAINERS: Glass Syringe, Glass Vials FORMULATION: Preservatives, Lyophilization, Conjugation CAPACITY: Analytical Testing, Drug Substance Production, Drug Product Production |
 POLYVAC | CONTAINERS: Glass Vials, Plastic Dropper FORMULATION: Adjuvants, Preservatives, Lyophilization CAPACITY: Secondary packaging, Analytical Testing, Drug Substance Production, Drug Product Production |
 Sinergium Biotech | CONTAINERS: Glass Syringe, Glass Vials FORMULATION: Adjuvants, Lyophilization CAPACITY: Secondary packaging, Analytical Testing, Drug Product Production |
 Sinovac Biotech Co., Ltd. | CONTAINERS: Glass Syringe, Glass Vials FORMULATION: Adjuvants, Conjugation CAPACITY: Secondary packaging, Analytical Testing, Drug Substance Production |
 SK bioscience Co., Ltd. | CONTAINERS: Glass Syringe, Glass Vials, Plastic Dropper FORMULATION: Preservatives, Lyophilization, Conjugation CAPACITY: Secondary packaging, Analytical Testing, Drug Substance Production, Drug Product Production |
 VINS BIOPRODUCTS LIMITED | CONTAINERS: Glass Syringe, Glass Vials, Ampoule FORMULATION: Adjuvants, Preservatives, Lyophilization CAPACITY: Secondary packaging, Drug Product Production |
 Xiamen Innovax Biotech Co., Ltd. | CONTAINERS: Glass Syringe, Glass Vials FORMULATION: CAPACITY: Analytical Testing, Drug Substance Production, Drug Product Production |
Disclaimer:
Each DCVMN member listed on this website has given its consent to it. The listing does not constitute or imply endorsement, recommendation or favouring by DCVMN.
All content is provided for information purposes only and does not constitute a legal contract, covenant or agreement of any kind. The information is updated periodically and without notification. No warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of any information or linked information. No liability is assumed in connection with use of the information on this site.
Expert Working Groups
Diphtheria and Tetanus Single Dilution Assay Project
The single dilution assay for the potency calculation of Diphtheria-Tetanus containing vaccines reduces the number of animals required for both the in vivo challenge and the serological potency assay. The single dilution is performed when the potency of the test vaccine consistently and significantly exceeds minimum requirements (i.e., the potency of the test vaccine is significantly greater than the minimum requirement per human dose for the product under test) and when parallelism between test and reference vaccine has been demonstrated over time.
The objective of the Diphtheria and Tetanus Single Dilution Assay Project is to support interested members participating to the project to create implementation plans (one per each company) of the single dilution assay. Members will receive dedicated support from external experts for the implementation of the in vivo challenge method. The project aims to create a communication channel between members and external experts on the topic, allowing all the parties to safely communicate respecting each other’s’ confidentiality.
*The project does not include support to members interested to transition from the in vivo challenge to the serological assay. If a minimum of 5 companies are interested to the transition from the in vivo to the serological assay, DCVMN will consider organizing a separate project and seek experts and funds. Furthermore, the participation to the project does not make the implementation of the Single Dilution Plans mandatory.
Familiarization with Monocyte Activation Test (MAT)
The 3Rs Working Group provided the members with a webinar, an e-learning course and a Virtual Reality experience to help members to familiarize with the Monocyte Activation Test (MAT), which is an alternative test to the Rabbit Pyrogenicity Test. The MAT is designed to test parenteral drugs, biologics and medical devices for all classifications of pyrogens. It employs human blood to simulate the first stages of the human immune system, and detect the presence of pyrogenic components. Another training opportunity to help members to improve their Quality Control process has been offered via a workshop on Statistical Analysis of Stability Testing, and two webinars dedicated to the “Development of simple and rapid UHPLC method for the quantification of 2-phenoxyethanol in vaccines)” and the “Next generation sequencing – Core technology in vaccinomics”.
Pertussis Serological Potency Test (PSPT) Consortium
The Pertussis Serological Potency Test (PSPT) Consortium, established by DCVMN in 2020 and funded by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), reached some important milestones within 2021. PSPT is closer to its goal than ever: to accelerate the laboratory implementation of the new testing assay – its regulatory acceptance, the reduction of animal testing which would consequently also reduce the final cost of the batches. The PSPT Standard Operating Procedures have been improved and guided by all the 10 participating laboratories in the performance of their in-house testing. The critical antigen reagent specific for the PSPT has been produced by a Contract Manufacturing Organization and distributed to all participating laboratories. Thirteen technical workshops were organized by DCVMN secretariat to inform, train and support laboratories in all the steps of the testing activities, and a dedicated data collection platform was created for anonymized data submission. The results of the testing were released mid-2022.
